TaiMed Biologics (ROCO:4147) Interest Expense: NT$-10.7 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$58.50
GF Value NT$86.15
Valuation Significantly Undervalued
View Full Analysis

What is TaiMed Biologics Interest Expense?

TaiMed Biologics ROCO:4147 -0.68% 55 Interest Expense is NT$-10.7 Mil as of Dec. 2025. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$86.15 (Significantly Undervalued).

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TaiMed Biologics's interest expense for the three months ended in Dec. 2025 was NT$ -2.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-10.7 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TaiMed Biologics's Operating Income for the three months ended in Dec. 2025 was NT$ -87.5 Mil. TaiMed Biologics's Interest Expense for the three months ended in Dec. 2025 was NT$ -2.6 Mil. TaiMed Biologics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TaiMed Biologics  (ROCO:4147) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TaiMed Biologics's Interest Expense for the three months ended in Dec. 2025 was NT$-2.6 Mil. Its Operating Income for the three months ended in Dec. 2025 was NT$-87.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was NT$463.0 Mil.

TaiMed Biologics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

TaiMed Biologics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

TaiMed Biologics Interest Expense Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics Interest Expense Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.44 -10.10 -14.81 -12.60 -10.71

TaiMed Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.14 -2.74 -2.68 -2.66 -2.63
ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-10.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of NT$-10.7 Mil mean?
TaiMed Biologics (ROCO:4147) has a Interest Expense of NT$-10.7 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on TaiMed Biologics and its competitors.
Is TaiMed Biologics' Interest Expense too high?
TaiMed Biologics' current Interest Expense is NT$-10.7 Mil. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Interest Expense compare to VRTX and REGN?
TaiMed Biologics' Interest Expense of NT$-10.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current Interest Expense is NT$-10.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$86.15, compared to a current price of NT$58.50 — trading 32.1% below its estimated fair value. The current Interest Expense is NT$-10.7 Mil. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Interest Expense is NT$-10.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$58.50 is trading 32.1% below its estimated GF Value™ of NT$86.15. GuruFocus considers TaiMed Biologics to be Significantly Undervalued.

Key valuation signals for ROCO:4147:

  • Interest Expense: NT$-10.7 Mil
  • GF Value™: NT$86.15 vs. price of NT$58.50 (32.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$58.50
Price
NT$86.15
GF Value